期刊文献+

特异性氨基酸代谢在前列腺癌中的研究进展

Research Progress of Specific Amino Acid Metabolism in Prostate Cancer
下载PDF
导出
摘要 近年代谢组学研究在肿瘤领域深入展开,其中前列腺癌特异性氨基酸代谢的差异性改变已用于前列腺癌的诊断和治疗。某些氨基酸生物合成代谢途径缺乏,会对前列腺癌细胞代谢产生特异影响,但对正常细胞却无影响,因此根据特异性氨基酸代谢的差异性行靶向治疗具有广泛的临床应用潜力。未来深入了解前列腺癌细胞中的氨基酸代谢变化及其相关的分子机制,可以为探究前列腺癌的病因、寻找新的靶向标志物以及制订个性化的治疗策略提供依据。 In recent years,metabolomics research has been deeply developed in the field of tumors,and some differential changes of prostate cancer specific amino acid metabolism have been used in the diagnosis and treatment of prostate cancer.Taking into account the lack of certain amino acid biosynthetic metabolic pathways,these metabolic pathways have a specific effect on the metabolism of prostate cancer cells,but have no effect on normal cells,so the targeted therapy has a wide range of clinical application potential.Understanding the amino acid metabolism changes in prostate cancer cells and the related molecular mechanisms can provide a basis for exploring the etiology,searching for new targeted markers,and developing individualized treatment strategies of prostate cancer.
作者 付成伟 张勇 董金凯 张景云 周礼 李学超 左世栋 孔令生 陈立军 FU Chengwei;ZHANG Yong;DONG Jinkai;ZHANG Jingyun;ZHOU Li;LI Xuechao;ZUO Shidong;KONG Lingsheng;CHEN Lijun(Senior Department of Urology,the Third Medical Center of PLA General Hospital,Beijing 100853,China;Department of Urology,the Fifth Medical Center of PLA General Hospital,Beijing 100071,China;Department of Military Preventive Medicine,PLA Army Military Medical University,Chongqing 400038,China)
出处 《医学综述》 CAS 2022年第11期2139-2144,共6页 Medical Recapitulate
关键词 前列腺癌 氨基酸代谢 线粒体 丝氨酸 肌氨酸 Prostate cancer Amino acid metabolism Mitochondria Serine Sarcosine
  • 相关文献

参考文献5

二级参考文献42

  • 1邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 2Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin, 2005, 55:74-108.
  • 3Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin, 2006, 56:106-130.
  • 4Michael PM, Bernard D, Kaill M, et al. Management of prostate cancer in China: a multicenter report of 6 institutions. J Urol, 2005, 174:1794-1797.
  • 5Murphy AM, McKiernan JM, Olsson CA. Controversies in prostate cancer screening. J Urol, 2004, 172 : 1822-1827.
  • 6Benaim EA, Pace CM, Roehrbor CG. Gleason score predicts androgen independent progression after androgen deprivation therapy. Eur Urel, 2002, 42:12-17.
  • 7Benaim EA, Pace CM, Lam PM, et al. Nadir PSA as a progression to androgeindependent prostate cancer. Urology, 2002, 59:73-77.
  • 8Siddall JK, Hetherington JW, Cooper EH, et al. Biochemical monitoring of carcinoma of prostate treated with an LRH analogue (Zoladex). Br J Urol, 1986, 58:676-679.
  • 9Mulders PF, Fernandez del MP, Theeuwes AG, et al. Value of biochemical markers in the management of disseminated prostatic cancer. Eur Urol, 1992, 21:2-7.
  • 10Darer A,Soret JY, Coblentz Y, et al. The usefulness of prostate- specific antigen and prostatic acid phosphatase in clinical practice. Am J Clin Oncol, suppl, 1988, 11 :S53-S57.

共引文献124

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部